Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

VCYT vs OPK: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

VCYT Wins Head-to-Head Institutional Verdict (4–2 across 6 Pillars · 7–3 Matrix Metrics)

VCYT Overall Winner 6-Pillar Tally: VCYT 4 – 2 OPK Matrix Metrics: VCYT 7 – 3 OPK

As of Nov 16, 2026, Veracyte, Inc. (VCYT) is the stronger overall head-to-head candidate over Opko Health Inc. (OPK) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). VCYT carries a Unified Composite Score of 49.1/100 (HOLD) at $24.01 (15.3x Forward P/E, 15.0% operating margin), whereas OPK carries 38.6/100 (SELL) at $1.62 (53.8x Forward P/E, -27.8% operating margin).

  • Technical & Structure Timing Caution: VCYT is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 27.8); meanwhile OPK trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 47.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About VCYT vs OPK
VCYT NASDAQ Head-to-Head Winner
Veracyte, Inc.
Services-Medical Laboratories
$24.01
-1.32% 1D
Market Cap $2.0B
TTM Revenue $582M
Forward P/E 15.3x
Beta / 30D Vol 3.01β · 199% Vol
Unified Composite Score
49.1 / 100 HOLD
Tech 55.0 Fund 56.0 Flow 57.0 Mom 55.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -3.8%), weak momentum, RSI 28
RSI-14: 27.8 · SMA20: $39.20 · SMA50: $41.79
OPK NASDAQ
Opko Health Inc.
Pharmaceutical Preparations
$1.62
-3.57% 1D
Market Cap $1.2B
TTM Revenue $654M
Forward P/E 53.8x
Beta / 30D Vol 0.77β · 31% Vol
Unified Composite Score
38.6 / 100 SELL
Tech 30.0 Fund 43.0 Flow 65.0 Mom 36.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 47
RSI-14: 47.0 · SMA20: $1.67 · SMA50: $1.60

6-Pillar Scorecard Institutional Category Breakdown (VCYT 4 – 2 OPK)

Columns: Metric · VCYT · OPK
1. Valuation Multiples VCYT
Forward P/E 15.3x 53.8x
Trailing P/E 15.8x 53.8x
PEG Ratio N/M N/M
EV / Revenue 3.1x 2.1x
2. Growth & Scale OPK
Revenue Growth (YoY) +15.1% +15.9%
Earnings Growth (YoY) +58.3% -12.6%
TTM Revenue (USD) $582M $654M
Market Cap $2.0B $1.2B
3. Profitability & Quality VCYT
Gross Margin 74.2% 19.6%
Operating Margin 15.0% -27.8%
Net Profit Margin 21.8% -22.6%
Return on Equity (ROE) 9.4% -8.9%
4. Balance Sheet & Cash Flow VCYT
Cash Generation (TTM) $162M -$136M
Cash Flow Margin 27.8% -20.8%
Net Cash / Leverage $159M Net Cash $125M Net Debt (0.46x D/E)
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning OPK
Options Structure Phase BREAKDOWN CONSOLIDATION
Current IV / %ile 197.3% (47th %ile) 58.9% (3rd %ile)
Put/Call OI Skew 0.01x (Call-Skewed) N/A
OBV Trend / Tech Phase DISTRIBUTION · Markdown DISTRIBUTION · Neutral
6. R&D & Supply-Chain Moat VCYT
OpEx & R&D Intensity 59.2% of Rev ($344M) 47.4% of Rev ($310M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Scale & Operating Efficiency Moat Cyclical / Execution-Driven Positioning
Supply-Chain Role Diagnostics & Research Operator Diagnostics & Research Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: VCYT (7) vs OPK (3)
Institutional Metric VCYT OPK Criterion Row Edge
Market Capitalization
Scale
$2.0B $1.2B Larger Scale VCYT
Trailing P/E Ratio
Valuation
15.8x 53.8x Lower Multiple VCYT
Forward P/E Ratio
Valuation
15.3x 53.8x Lower Multiple VCYT
Revenue Growth (YoY)
Growth
+15.1% +15.9% Higher Growth OPK
Operating Margin (TTM)
Profitability
15.0% -27.8% Higher Margin VCYT
Net Profit Margin
Profitability
21.8% -22.6% Higher Margin VCYT
Return on Equity (ROE)
Capital Efficiency
9.4% -8.9% Higher ROE VCYT
52-Week Range Position
Momentum
5% ($22–$61) 73% ($1–$2) Stronger Trend OPK
Beta / 30D Volatility
Risk Regime
3.01β · 199% Vol 0.77β · 31% Vol Lower Realized Risk OPK
Unified Institutional Score
Composite Signal
49.1 / 100 (HOLD) 38.6 / 100 (SELL) Higher Composite VCYT
Trailing 12M Revenue (USD)
Operating Scale
$582M $654M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
74.2% 19.6% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 3.1x EV/Rev N/M PEG · 2.1x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
$162M ($159M Net Cash) -$136M ($125M Net Debt (0.46x D/E)) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon OPK +50.2 pp
VCYT: -44.32% · OPK: +5.88%
3M Horizon OPK +60.1 pp
VCYT: -40.98% · OPK: +19.12%
6M Horizon OPK +85.5 pp
VCYT: -42.14% · OPK: +43.36%
1Y Horizon OPK +66.34 pp
VCYT: -39.78% · OPK: +26.56%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period VCYT Revenue OPK Revenue VCYT Op. Margin OPK Op. Margin Margin Leader
FY2018 $90M $990M -24.2% -17.3% OPK
FY2019 $120M $900M -12.6% -30.4% VCYT
FY2020 $120M $1.44B -30.1% 4.0% OPK
FY2021 $220M $1.77B -37.3% 1.1% OPK
FY2022 $300M $1.00B -13.9% -22.5% VCYT
FY2023 $360M $860M -23.8% -18.2% OPK
FY2024 $450M $710M 3.6% -21.3% VCYT
FY2025 $520M $610M 11.2% -19.3% VCYT

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
VCYT BREAKDOWN
99d in phase · OBV DISTRIBUTION
Current IV 197.3%
IV Percentile 47th %ile
Put/Call OI Skew 0.01x (Call-Skewed)
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BEARISH
OBV Flow DISTRIBUTION
Exact VCYT Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
OPK CONSOLIDATION
78d in phase · OBV DISTRIBUTION
Current IV 58.9%
IV Percentile 3rd %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow DISTRIBUTION
Exact OPK Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
VCYT Moat Profile Scale & Operating Efficiency Moat
Diagnostics & Research Operator
Competes within the Diagnostics & Research value chain with $2.0B market capitalization and 15.0% operating margin.
OpEx & R&D Reinvestment 59.2% of Rev ($344M)
90D Engineering Disclosures 0 Published
OPK Moat Profile Cyclical / Execution-Driven Positioning
Diagnostics & Research Operator
Competes within the Diagnostics & Research value chain with $1.2B market capitalization and -27.8% operating margin.
OpEx & R&D Reinvestment 47.4% of Rev ($310M)
90D Engineering Disclosures 0 Published

Investor FAQ VCYT vs OPK Key Questions & Quantitative Answers

As of Nov 16, 2026, Veracyte, Inc. (VCYT) is the stronger overall head-to-head candidate over Opko Health Inc. (OPK) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). VCYT carries a Unified Composite Score of 49.1/100 (HOLD) at $24.01 (15.3x Forward P/E, 15.0% operating margin), whereas OPK carries 38.6/100 (SELL) at $1.62 (53.8x Forward P/E, -27.8% operating margin). Technical & Structure Timing Caution: VCYT is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 27.8); meanwhile OPK trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 47.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

OPK leads the Growth & Scale pillar: VCYT posts +15.1% YoY revenue growth and +58.3% YoY earnings growth on $582M TTM revenue (74.2% gross margin, 15.0% operating margin), compared with OPK at +15.9% YoY revenue growth and -12.6% YoY earnings growth on $654M TTM revenue (19.6% gross margin, -27.8% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), VCYT cumulative revenue shifted +477.8% while OPK shifted -38.4%. In operating R&D and SG&A reinvestment, VCYT deploys 59.2% of Rev ($344M) (0 90-day corporate R&D disclosures) versus 47.4% of Rev ($310M) (0 disclosures) for OPK.

VCYT screens cheaper on headline valuation multiples. VCYT trades at 15.3x Forward P/E, 15.8x Trailing P/E, N/M PEG, and 3.1x EV/Revenue (27.8% FCF margin), whereas OPK trades at 53.8x Forward P/E, 53.8x Trailing P/E, N/M PEG, and 2.1x EV/Revenue (-20.8% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against VCYT (9.4% ROE) versus OPK (-8.9% ROE) capital efficiency.

In options market volatility and institutional positioning, VCYT carries 197.3% implied volatility (47th %ile, Balanced (25th–60th %ile)), a 0.01x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (3.01β · 199% Vol realized risk). By comparison, OPK carries 58.9% implied volatility (3rd %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, DISTRIBUTION on-balance volume, and sits in a CONSOLIDATION options structure phase (0.77β · 31% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.